Ordering
Available Variants5 mg
CHA.69805-5mg
Price
€119.00
Available – Dispatch in 14 days
25 mg
CHA.69805-25mg
Price
€470.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.69805-5mg | €119.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.69805-25mg | €470.40 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C21H24ClFN4O3 |
|---|---|
| CAS Number | 217645-70-0 |
| Molecular Weight | 434.89 |
| UNSPSC Code | 51111800 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
| Storage condition | desiccated |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
BX471, also known as CAS 288262-96-4, is a potent and selective inhibitor of the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. This compound has been extensively studied for its potential therapeutic applications in the treatment of various cancers, including solid tumors and hematological malignancies. By inhibiting VEGFR, BX471 disrupts the signaling pathways that regulate angiogenesis, thereby preventing the formation of new blood vessels that supply nutrients to growing tumors. As a result, BX471 has been shown to exhibit anti-tumor activity and reduce tumor growth in preclinical models. Further research is needed to fully elucidate the clinical potential of BX471 and its potential use in combination with other anti-cancer therapies to enhance treatment outcomes. The compounds mechanism of action and pharmacological properties make it an attractive candidate for further investigation.
